Toxicity of Locoregional Radiotherapy in Combination With Bevacizumab in Patients With Non-Metastatic Breast Cancer (TOLERAB): Final Long-Term Evaluation

PLoS ONE - United States
doi 10.1371/journal.pone.0221816
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

A Phase II Trial of Erlotinib in Combination With Bevacizumab in Patients With Metastatic Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2008English

Association of Body Composition With Long-Term Survival in Non-Metastatic Rectal Cancer Patients

Cancer Research and Treatment
Cancer ResearchOncology
2020English

P3-027Liver Cirrhosis Associated With Paclitaxel and Bevacizumab Combination Therapy in a Metastatic Breast Cancer Patient

Annals of Oncology
MedicineOncologyHematology
2018English

Disease-Free Survival in Patients With Non-Metastatic Breast Cancer

Revista da Associacao Medica Brasileira
Medicine
2016English

Immediate and Long-Term Outcomes of Drug Treatment in Patients With Metastatic Triple Negative Breast Cancer

Malignant tumours
2018English

Individualized Prediction of Survival Benefit From Locoregional Surgical Treatment for Patients With Metastatic Breast Cancer

Frontiers in Oncology
Cancer ResearchOncology
2020English

Long-Term Results of Combination Treatment in Patients With Disseminated Rectal Cancer

Onkologiya. Zhurnal imeni P.A.Gertsena
2017English

Neuropsychological Evaluation of Patients With Inoperable Non-Small Cell Lung Cancer Treated With Combination Chemotherapy or Radiotherapy

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
1988English

Contraindicated Use of Bevacizumab and Toxicity in Elderly Patients With Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy